The health services industry is also showing some bright spots. The Danish company Novo Nordisk (NVO), specializing in diabetes care and hormone therapy, has been performing very well since mid-November of last year and is up over 16 percent year-to-date. With a cap of $85.93 billion, sales at $13.75 billion, and forward P/E ratio of $23.27, analysts are rating NVO right now as a strong buy, and this is reflected in its current share price of $192.69 (up over 25 percent since last November).
Celldex Therapeutics (CLDX) is another such example, up 10.5 percent this year. According to their website, CLDX is “the first anti-body based combination Immunotherapy Company” that specializes in cancer and other difficult-to-treat medical conditions. Sporting relatively more modest cap and sales figures ($459.89 million and $10 million respectively), their stock price has climbed rather quickly to $7.68 since last November when it was at $5. While the company is still too young to have any reliable projections figures, the nature of their work and the fact that they are also being rated as a Strong Buy are facts that suggest they should by all means be kept on the radar.
Finally, Delek Logistics Partners LP (DKL), a new U.S.-based independent oil and gas company that owns pipeline, transportation, and marketing assets, has put up a strong performance with an over 13 percent gain year-to-date. Its cap is currently at $625.44 million, while sales are at $960.37 million, and its share price has climbed rather quickly to $26.47. Add to that a forward P/E of 17.14 percent, and an EPS for the next year projected at 78.82 percent, this company is another one to keep an eye on throughout 2013.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer